Mark C. Scholz
Papers
1
Total Citations
459
H-Index
1
About
Mark C. Scholz is a leading authority in prostate cancer research, with a primary focus on risk-stratified treatment outcomes and the clinical utility of prostate-specific antigen (PSA) as a biomarker. His most influential contribution is the landmark 2012 study from the Prostate Cancer Results Study Group, which systematically compared PSA-free survival outcomes across low, intermediate, and high-risk prostate cancer patients treated with radical therapies. This work, cited over 459 times, provided critical evidence that PSA is the most sensitive tool for measuring treatment effectiveness, filling a gap in comparative studies that previously lacked standardized metrics. Scholz’s research has directly shaped clinical decision-making by clarifying how risk classification influences post-treatment prognosis. Beyond this, his work underscores the importance of evidence-based guidelines in urologic oncology, helping clinicians and patients navigate the complex landscape of prostate cancer management. His contributions have been instrumental in advancing personalized treatment strategies, making him a respected voice in the field.
Research Focus
Key Achievements
Top Papers
- 1